Skip to content

Released Mar 19, 2026, after the close

10-K filed Mar 19, 2026, 78 days after period end · 0001193125-26-115992

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$42.47Mderived+477.3% vs Q4 2024+293.6% vs Q3 2025
Net Income$22.09MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$19,799,000N/M
Operating Cash Flowderived$14,237,000N/M
Free Cash Flowderived$14,213,000N/M
Margins · derived
Operating margin46.6%+203.4 pt vs Q4 2024
Net margin52.0%+192.5 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$42.47M$7.36M$7.16M—
Net Income$22.09M-$10.34M-$10.96M-$22.40M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR